In summary, NAT10 is associated with poor prognosis in patients with ccRCC and may be used as a biomarker for the occurrence and progression of ccRCC, as well as a potential target for future clinical diagnosis and treatment of ccRCC. The gene discussed is NAT10; the disease is nonpapillary renal cell carcinoma.